Kelun-Biotech to present two registrational studies in the oral presentation session on non-small cell lung cancer at ASCO 2026

[출처/시간] Briefing.com - 6:45 AM ET, 05/22/2026

The results demonstrated that:Significant PFS improvement: PFS assessed by BICR was significantly improved in the sac-TMT plus pembrolizumab group compared with the pembrolizumab group, with a median PFS of not reached (NR) versus 5.7 months (hazard ratio (HR)=0.35; 95% confidence interval (CI): 0.26--0.47; p<0.0001).Substantially higher response rate: The objective response rate (ORR) assessed by BICR was 70.2% in the sac-TMT plus pembrolizumab group versus 42.0% in the pembrolizumab group.Positive OS trend though immature (HR=0.55; 95% CI: 0.36--0.85).Consistent benefit across prespecified subgroups: the HR for PFS in patients with PD-L1 TPS 1-49% and TPS = 50% were 0.28 (95% CI, 0.19-0.41) and 0.47 (95% CI, 0.29-0.77), respectively; the HR for PFS in patients with non-squamous and squamous NSCLC were 0.28 (95% CI, 0.18-0.43) and 0.44 (95% CI, 0.29-0.66).In terms of safety, grade= 3 treatment-emergent adverse events (TEAEs) occurred in 55.3% of patients in the sac-TMT plus pembrolizumab group versus 31.4% in the pembrolizumab group. TEAEs leading to permanent discontinuation of sac-TMT and pembrolizumab occurred in 3.8% and 5.3% of patients, respectively, while TEAEs leading to permanent discontinuation occurred in 4.9% of patients in the pembrolizumab group.In May 2022, the Company licensed the exclusive rights to Merck (MRK) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).